Pharma BD Deal Intelligence
AstraZeneca licensed exclusive ex-China rights to Jacobio's JAB-23E73, a Phase 1 pan-KRAS inhibitor (oral small molecule sparing HRAS/NRAS), announced December 21, 2025. Jacobio receives $100M upfront and up to $1.915B in development/commercial milestones plus tiered royalties; Jacobio retains co-development/commercialization rights in China (total up to ~$2.015B). The agreement became effective with Jacobio confirming receipt of the $100M upfront on March 30, 2026. JAB-23E73 has produced the first clinical data for a pan-KRAS inhibitor: in the China Phase 1a dose-escalation (42 patients as of Jan 15, 2026) multiple confirmed partial responses were seen, with a 38.5% ORR and 84.6% DCR among 13 pancreatic-cancer patients in the efficacious dose range and Grade 3 TRAEs of 11.9% (no Grade 4/5). China's CDE approved a Phase 1/3 first-line KRAS-mutant pancreatic combination (nab-paclitaxel + gemcitabine) in February 2026.